Published on 6 Oct 2024 on GuruFocus.com · via Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating...
Research and Development Expenses: $7.6 million for the quarter ending June 30, 2024, compared to $4.2 million for the same period last year.General and Administrative Expenses: $4.6 million for the quarter ending June 30, 2024, compared to $3 million for the same period last year.Net Loss: $10.7 million for the quarter ended June 30, 2024, compared to $6.9 million for the same period last year.Cash, Cash Equivalents, and Marketable Securities: $108.4 million as of June 30, 2024.